Akero Therapeutics
Akero Therapeutics (AKRO) - a clinical-stage company, today released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).
The study met its primary endpoint for both the 50mg . . .
This content is for paid subscribers.
Today’s Highlights
September 13, 2022